Janssen grabs up oncolytic virus company BeneVir

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) is acquiring oncolytic virus company BeneVir Biopharm Inc. (Rockville, Md.).

BeneVir

Read the full 208 word article

User Sign In